FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200140147> ?p ?o ?g. }

• W4200140147 abstract "A vaccine against coronavirus disease 2019 (COVID-19) with highly effective protection is urgently needed. The anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody response and duration after vaccination are crucial predictive indicators.To evaluate the response and duration for 5 subsets of anti-SARS-CoV-2 antibodies after vaccination and their predictive value for protection.We determined the response and duration for 5 subsets of anti-SARS-CoV-2 antibodies (neutralizing antibody, anti-RBD total antibody, anti-Spike IgG, anti-Spike IgM, and anti-Spike IgA) in 61 volunteers within 160 days after the CoronaVac vaccine. A logistic regression model was used to determine the predictors of the persistence of neutralizing antibody persistence.The seropositivity rates of neutralizing antibody, anti-RBD total antibody, anti-Spike IgG, anti-Spike IgM, and anti-Spike IgA were only 4.92%, 27.87%, 21.31%, 3.28% and 0.00%, respectively, at the end of the first dose (28 days). After the second dose, the seropositivity rates reached peaks of 95.08%, 100.00%, 100.00%, 59.02% and 31.15% in two weeks (42 days). Their decay was obvious and the seropositivity rate remained at 19.67%, 54.10%, 50.82%, 3.28% and 0.00% on day 160, respectively. The level of neutralizing antibody reached a peak of 149.40 (101.00-244.60) IU/mL two weeks after the second dose (42 days) and dropped to 14.23 (7.62-30.73) IU/mL at 160 days, with a half-life of 35.61(95% CI, 32.68 to 39.12) days. Younger participants (≤31 years) had 6.179 times more persistent neutralizing antibodies than older participants (>31 years) (P<0.05). Participants with anti-Spike IgA seropositivity had 4.314 times greater persistence of neutralizing antibodies than participants without anti-Spike IgA seroconversion (P<0.05).Antibody response for the CoronaVac vaccine was intense and comprehensive with 95.08% neutralizing seropositivity rate, while decay was also obvious after 160 days. Therefore, booster doses should be considered in the vaccine strategies." @default.
• W4200140147 created "2021-12-31" @default.
• W4200140147 creator A5052501165 @default.
• W4200140147 creator A5055927309 @default.
• W4200140147 creator A5056939900 @default.
• W4200140147 creator A5058617112 @default.
• W4200140147 creator A5062316263 @default.
• W4200140147 creator A5070145793 @default.
• W4200140147 creator A5071675363 @default.
• W4200140147 creator A5072769611 @default.
• W4200140147 creator A5075734545 @default.
• W4200140147 date "2021-12-23" @default.
• W4200140147 modified "2023-10-12" @default.
• W4200140147 title "Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days" @default.
• W4200140147 cites W2093901235 @default.
• W4200140147 cites W2900791144 @default.
• W4200140147 cites W2963441282 @default.
• W4200140147 cites W3013893246 @default.
• W4200140147 cites W3022917947 @default.
• W4200140147 cites W3035459690 @default.
• W4200140147 cites W3081916995 @default.
• W4200140147 cites W3108193091 @default.
• W4200140147 cites W3111255098 @default.
• W4200140147 cites W3112028440 @default.
• W4200140147 cites W3112389805 @default.
• W4200140147 cites W3117382778 @default.
• W4200140147 cites W3119180698 @default.
• W4200140147 cites W3119953480 @default.
• W4200140147 cites W3121008609 @default.
• W4200140147 cites W3121906900 @default.
• W4200140147 cites W3123175540 @default.
• W4200140147 cites W3131938123 @default.
• W4200140147 cites W3132982761 @default.
• W4200140147 cites W3138645734 @default.
• W4200140147 cites W3140400537 @default.
• W4200140147 cites W3163785571 @default.
• W4200140147 cites W3165443674 @default.
• W4200140147 cites W3180567859 @default.
• W4200140147 cites W3181110129 @default.
• W4200140147 cites W3182677184 @default.
• W4200140147 cites W3182898074 @default.
• W4200140147 cites W3206370075 @default.
• W4200140147 doi "https://doi.org/10.3389/fimmu.2021.786554" @default.
• W4200140147 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35003104" @default.
• W4200140147 hasPublicationYear "2021" @default.
• W4200140147 type Work @default.
• W4200140147 citedByCount "29" @default.
• W4200140147 countsByYear W42001401472022 @default.
• W4200140147 countsByYear W42001401472023 @default.
• W4200140147 crossrefType "journal-article" @default.
• W4200140147 hasAuthorship W4200140147A5052501165 @default.
• W4200140147 hasAuthorship W4200140147A5055927309 @default.
• W4200140147 hasAuthorship W4200140147A5056939900 @default.
• W4200140147 hasAuthorship W4200140147A5058617112 @default.
• W4200140147 hasAuthorship W4200140147A5062316263 @default.
• W4200140147 hasAuthorship W4200140147A5070145793 @default.
• W4200140147 hasAuthorship W4200140147A5071675363 @default.
• W4200140147 hasAuthorship W4200140147A5072769611 @default.
• W4200140147 hasAuthorship W4200140147A5075734545 @default.
• W4200140147 hasBestOaLocation W42001401471 @default.
• W4200140147 hasConcept C126322002 @default.
• W4200140147 hasConcept C159047783 @default.
• W4200140147 hasConcept C159654299 @default.
• W4200140147 hasConcept C203014093 @default.
• W4200140147 hasConcept C22070199 @default.
• W4200140147 hasConcept C2779134260 @default.
• W4200140147 hasConcept C2779261636 @default.
• W4200140147 hasConcept C2909509916 @default.
• W4200140147 hasConcept C3008058167 @default.
• W4200140147 hasConcept C3018913218 @default.
• W4200140147 hasConcept C524204448 @default.
• W4200140147 hasConcept C71924100 @default.
• W4200140147 hasConceptScore W4200140147C126322002 @default.
• W4200140147 hasConceptScore W4200140147C159047783 @default.
• W4200140147 hasConceptScore W4200140147C159654299 @default.
• W4200140147 hasConceptScore W4200140147C203014093 @default.
• W4200140147 hasConceptScore W4200140147C22070199 @default.
• W4200140147 hasConceptScore W4200140147C2779134260 @default.
• W4200140147 hasConceptScore W4200140147C2779261636 @default.
• W4200140147 hasConceptScore W4200140147C2909509916 @default.
• W4200140147 hasConceptScore W4200140147C3008058167 @default.
• W4200140147 hasConceptScore W4200140147C3018913218 @default.
• W4200140147 hasConceptScore W4200140147C524204448 @default.
• W4200140147 hasConceptScore W4200140147C71924100 @default.
• W4200140147 hasFunder F4320321001 @default.
• W4200140147 hasLocation W42001401471 @default.
• W4200140147 hasLocation W42001401472 @default.
• W4200140147 hasLocation W42001401473 @default.
• W4200140147 hasOpenAccess W4200140147 @default.
• W4200140147 hasPrimaryLocation W42001401471 @default.
• W4200140147 hasRelatedWork W169470829 @default.
• W4200140147 hasRelatedWork W2015795418 @default.
• W4200140147 hasRelatedWork W2132089352 @default.
• W4200140147 hasRelatedWork W2163895276 @default.
• W4200140147 hasRelatedWork W4200140147 @default.
• W4200140147 hasRelatedWork W4221060475 @default.
• W4200140147 hasRelatedWork W4292337239 @default.
• W4200140147 hasRelatedWork W4310873631 @default.
• W4200140147 hasRelatedWork W4362525497 @default.
• W4200140147 hasRelatedWork W1510441201 @default.

• next